Indeed, multiple studies assessing administration of these inhibitors, including on the same day, reported that specifically inhibiting MCL-1 and BCL-2 was effective at reducing tumor burden, without overt toxicity concerns [17–19,36,64–66]. The gene discussed is MCL1; the disease is neoplasm.